Dupixent is a brand-name injection that doctors prescribe to treat certain conditions, including atopic dermatitis and asthma. Injection site reactions, such as pain, are common side effects of ...

Dupixent (dupilumab) is a prescription drug that’s used to treat certain inflammatory conditions. The drug comes as a solution for injection under the skin. How often you’ll receive a dose ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...

The FDA has accepted the resubmitted sBLA for Regeneron/Sanofi's Dupixent to treat CSU in patients aged 12+ unresponsive to H1 antihistamine Dupixent's resubmission is backed by LIBERTY-CUPID ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use of Dupixent ...

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks. Approximately 44 million COPD cases were recorded in 2023 in the 7MM ...

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or EoE, in children as young as one year of age.

(REGN) announced Friday that the U.S. Food and Drug Administration has accepted for review the resubmission of the supplemental biologics license application or sBLA for Dupixent (dupilumab ...